QUILT-3.080: NANT Pancreatic Cancer Vaccine

Pancreatic Cancer Clinical Trial

Official title:

QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03586869
• Other study ID #: QUILT-3.080
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 28, 2018
• Est. completion date: December 2019

Study information

• Verified date: July 2019
• Source: NantKwest, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.

Description:

Treatment will be administered in two phases, an induction and a maintenance phase, as described below. Subjects will continue induction treatment for up to 1 year. Treatment in the study will be discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) at 1 year may enter the maintenance phase at the Investigator's discretion. Subjects may remain on the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. The maximum time on study treatment, including both the induction and maintenance phases, is 2 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 173
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years old.

2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.

3. Histologically-confirmed pancreatic adenocarcinoma with progression on or after SoC therapy.

4. ECOG performance status of 0 to 2.

5. Have at least 1 measurable lesion of = 1.0 cm.

6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.

7. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.

8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.

9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, and abstinence.

Exclusion Criteria:

1. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.

2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).

3. History of organ transplant requiring immunosuppression.

4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

5. Inadequate organ function, evidenced by the following laboratory results:

1. Absolute neutrophil count < 1,000 cells/mm3.

2. Platelet count < 75,000 cells/mm3.

3. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).

4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).

5. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).

6. Serum creatinine > 2.0 mg/dL or 177 µmol/L.

7. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3.

8. Medically uncorrectable grade 3 anemia (hemoglobin < 8 g/dL).

6. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.

7. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) 10% below the institution's lower limit of predicted normal.

8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.

9. Positive results of screening test for human immunodeficiency virus (HIV).

10. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.

11. Known hypersensitivity to any component of the study medication(s).

12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.

13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.

14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.

15. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to initiation of treatment on this study, except for receipt of testosterone-lowering therapy in men with prostate cancer, or treatment with any NANT Cancer Vaccine therapy.

16. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.

17. Concurrent participation in any interventional clinical trial.

18. Pregnant and nursing women.

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Aldoxorubicin HCl
Aldoxorubicin Hydrochloride

Biological:
• ALT-803
Recombinant human super agonist interleukin-15 (IL-15) complex
• ETBX-011
Ad5 [E1-, E2b-]-CEA
• ETBX-021
Ad5 [E1-, E2b-]-HER2
• ETBX-051
Ad5 [E1-, E2b-]-Brachyury
• ETBX-061
Ad5 [E1-, E2b-]-MUC1
• GI-4000
RAS yeast
• GI-6207
Carcinoembryonic Antigen (CEA) yeast
• GI-6301
Brachyury yeast
• haNK for infusion
NK-92 [CD16.158V, ER IL-2]
• bevacizumab
Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal

Drug:
• Capecitabine
5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
• Cyclophosphamide
2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
• Fluorouracil
5-fluoro-2,4 (1H,3H)-pyrimidinedione
• Leucovorin
L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
• nab-Paclitaxel
Benzenepropanoic acid, ß-(benzoylamino)-a-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(aR,ßS)-(9CI) bound to albumin
• Oxaliplatin
cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum

Biological:
• Avelumab
Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody

Procedure:
• SBRT
Stereotactic Body Radiation Therapy

Locations

Country	Name	City	State
United States	Chan Soon-Shiong Institute for Medicine	El Segundo	California

Sponsors (1)

Lead Sponsor	Collaborator
NantKwest, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall Response Rate by immune-related Response Criteria (irRC)	Phase 1b and 2 Secondary Outcome	2 years
Other	Progression Free Survival by RECIST Version 1.1	Phase 1b and 2 Secondary Outcome	2 years
Other	Progression Free Survival by irRC	Phase 1b and 2 Secondary Outcome	2 years
Other	Overall Survival	Phase 1b and 2 Secondary Outcome	2 years
Other	Duration Of Response by RECIST Version 1.1 and irRC	Phase 1b and 2 Secondary Outcome	2 years
Other	Disease Control Rate (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months) by RECIST and irRC	Phase 1b and 2 Secondary Outcome	2 years
Other	Quality of Life by patient-reported outcomes (PROs)	Phase 1b and 2 Secondary Outcome	2 years
Primary	Incidence of treatment-emergent adverse events (AEs), graded using the NCI CTCAE Version 4.03	Phase 1b Primary Outcome	2 years
Primary	Incidence of treatment-emergent serious adverse events (SAEs), graded using the NCI CTCAE Version 4.03	Phase 1b Primary Outcome	2 years
Primary	Overall Response Rate by RECIST Version 1.1	Phase 2 Primary Outcome	2 years
Secondary	ORR by RECIST Version 1.1	Phase 1b Secondary Outcome	2 years